Rationale and design of randomized, double-blind trial evaluating the efficacy of single-dose HPV vaccine efficacy in women aged 18 to 30: The PRISMA trial.
Abstract
Evidence from the Costa Rica HPV Vaccine Trial suggested that a single dose may provide durable protection in young adult women. Subsequent studies confirmed the non-inferiority of one vs. two doses of the main vaccines among young girls. Vaccination of older cohorts might accelerate cervical cancer elimination, especially if a single dose provides adequate protection. Randomized data are needed to support extended-age, single-dose vaccination strategies. Herein, we present the design, rationale and recruitment results of a three-arm, randomized, double-blinded, clinical trial in Costa Rica to evaluate the efficacy of a single dose of the bivalent (Cervarix®) and nonavalent (Gardasil 9®) HPV vaccines compared with an active control (Tdap). 4925 HPV vaccine-naïve women aged 18-30 years old were enrolled, randomized 1:1:1, and followed for 36 months with cervicovaginal self-sampling every six months starting at 12 months, annual blood collection, and oral/anal sampling at selected visits, with high participation rates. Participants attended ~90% of planned study visits and >96% of attendees provided the necessary specimens. The primary endpoint is incident cerviccovaginal HPV16/18 infection persisting ≥6 months among women HPV16/18 DNA-negative at the enrollment and vaccination visits. Secondary endpoints include vaccine efficacy in the intention-to-treat cohort, oral and anal HPV16/18 protection, and immunogenicity profiles. Trial results will inform mathematical models estimating impact and cost-effectiveness of extending single-dose vaccination to adult young women and directly inform policy to enable extended-age, single-dose strategies to accelerate cervical cancer prevention globally. Furthermore, the study will provide the first evidence for single-dose efficacy against anal and oral HPV infection.